Momenta files Investigational New Drug application for anticoagulant to treat acute coronary syndrome

By Lisa Kerner

Charlotte, N.C., July 31 - Momenta Pharmaceuticals, Inc. said it has submitted an electronic Investigational New Drug application to the Food and Drug Administration to begin a phase 1 human clinical study of M118, an anticoagulant designed to treat acute coronary syndromes (ACS).

ACS patients are those experiencing an acute myocardial infarction (heart attack) or with unstable angina.

M118, with a pharmacokinetic profile similar to a low molecular weight heparin, has been shown to be at least as effective in inhibiting clot formation as unfractionated heparin without causing increased bleeding complications, the company said.

"M118 has the potential to be a significant future advancement in the treatment and management of ACS," chief executive officer Alan Crane said in a company news release.

"We are very encouraged by our preclinical studies which show that M118 could be a potent agent that provides consistent, flexible and reversible anticoagulant therapy."

Momenta is a biotechnology located in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.